Virax Biolabs Files October 2024 6-K Report
Ticker: VRAX · Form: 6-K · Filed: Oct 23, 2024 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, administrative
TL;DR
Virax Biolabs filed a 6-K for October, confirming 20-F annual reports. Standard admin update.
AI Summary
On October 23, 2024, Virax Biolabs Group Ltd. filed a Form 6-K with the SEC. This report is for the month of October 2024 and indicates that the company files annual reports under Form 20-F. The filing provides the company's principal executive office address in Lanarkshire, United Kingdom.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and administrative details.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Virax Biolabs Group Ltd. (company) — Registrant
- 001-41440 (company) — SEC File Number
- 20241023 (date) — Filing Date
- October 2024 (date) — Reporting Period
FAQ
What type of SEC filing is this?
This is a Form 6-K report, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the reporting period for this Form 6-K?
The report is for the month of October 2024.
Does Virax Biolabs Group Ltd. file annual reports under Form 20-F or 40-F?
The company indicates that it files annual reports under Form 20-F.
What is the principal executive office address of Virax Biolabs Group Ltd.?
The principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.
What is the SEC file number for Virax Biolabs Group Ltd.?
The SEC file number is 001-41440.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-10-23 08:50:47
Filing Documents
- 6-k_europa_biosite_distr.htm (6-K) — 24KB
- vrax-ex99_1.htm (EX-99.1) — 10KB
- 0000950170-24-116493.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: April 16, 2024 By: /s/ James Foster James Foster, Chief Executive Officer